Kepivance(palifermin)
Kepivance (palifermin) is a protein pharmaceutical. Palifermin was first approved as Kepivance on 2004-12-15. It is used to treat mucositis in the USA. It has been approved in Europe to treat mucositis. The pharmaceutical is active against fibroblast growth factor receptor 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| digestive system diseases | D004066 |
| stomatognathic diseases | D009057 |
Trade Name
FDA
EMA
Kepivance
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Palifermin
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Kepivance | palifermin | Orphan Medical | N-125103 RX | 2004-12-15 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| kepivance | Biologic Licensing Application | 2024-12-20 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| mucositis | EFO_1001898 | D052016 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2425 | Injection, palifermin, 50 micrograms |
Clinical
Clinical Trials
60 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 1 | 1 | 1 | 1 | — | 4 |
| Mucositis | D052016 | EFO_1001898 | — | 1 | 1 | 2 | 1 | — | 4 |
| Lymphoma | D008223 | — | C85.9 | 1 | — | 1 | 1 | — | 3 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 1 | — | 1 | — | 2 |
| Plasma cell neoplasms | D054219 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomatitis | D013280 | EFO_1001904 | K12.1 | 3 | 2 | 3 | — | — | 7 |
| Neoplasms | D009369 | — | C80 | 2 | 2 | 3 | — | — | 5 |
| Leukemia | D007938 | — | C95 | 2 | 1 | 1 | — | — | 4 |
| Head and neck neoplasms | D006258 | — | — | 2 | 2 | 1 | — | — | 3 |
| Cataract | D002386 | EFO_0001059 | H26.9 | — | — | 1 | — | — | 1 |
| Squamous cell carcinoma | D002294 | — | — | — | — | 1 | — | — | 1 |
| Squamous cell neoplasms | D018307 | — | — | — | — | 1 | — | — | 1 |
| Xerostomia | D014987 | — | K11.7 | — | — | 1 | — | — | 1 |
| Laryngeal diseases | D007818 | — | J38.7 | — | — | 1 | — | — | 1 |
| Oral ulcer | D019226 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | — | — | — | 1 | — | — | — | 1 |
| Graft vs host disease | D006086 | — | D89.81 | — | 1 | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | — | 1 | — | — | — | 1 |
| Deglutition disorders | D003680 | — | R13.1 | — | 1 | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 1 | — | — | — | 1 |
| Stevens-johnson syndrome | D013262 | EFO_0004276 | L51.1 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Palifermin |
| INN | palifermin |
| Description | Palifermin (trade name Kepivance, marketed by Biovitrum) is a truncated human recombinant keratinocyte growth factor (KGF) produced in Escherichia coli. KGF stimulates the growth of cells that line the surface of the mouth and intestinal tract.
|
| Classification | Protein |
| Drug class | growth factors: fibroblast growth factors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201821 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00039 |
| UNII ID | QMS40680K6 (ChemIDplus, GSRS) |
Target
Agency Approved
FGFR2
FGFR2
Organism
Homo sapiens
Gene name
FGFR2
Gene synonyms
BEK, KGFR, KSAM
NCBI Gene ID
Protein name
fibroblast growth factor receptor 2
Protein synonyms
bacteria-expressed kinase, BEK fibroblast growth factor receptor, CD332, K-sam, Keratinocyte growth factor receptor, KGFR, protein tyrosine kinase, receptor like 14
Uniprot ID
Mouse ortholog
Fgfr2 (14183)
fibroblast growth factor receptor 2 (P21803)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 853 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
500 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use